Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Volume:8 Issue:4 Number:17 ISSN#:2564-2537
Author Verified
ACE Report #11001
Ace Report Cover Metabolic Disorders

Significant reduction in 6-year fragility fracture risk with zoledronate vs placebo for osteopenia

How to Cite

OrthoEvidence. Significant reduction in 6-year fragility fracture risk with zoledronate vs placebo for osteopenia. ACE Report. 2019;8(4):17. Available from: https://myorthoevidence.com/AceReport/Report/11001

Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A

Fracture Prevention with Zoledronate in Older Women with Osteopenia

N Engl J Med. 2018 Dec 20;379(25):2407-2416. doi: 10.1056/NEJMoa1808082

Contributing Authors: IR Reid S Wong MJ Bolland GD Gamble B Mihov AM Horne A Stewart E Garratt KR Wiessing S Bastin

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


2000 postmenopausal women with osteopenia were randomized to treatment with infusion of either zoledronate 5mg or placebo every 18 months for 6 years. Participants were assessed for incidence of fractures, prespecified adverse events including mortality, vascular events, cancer, and osteonecrosis of the jaw, and bone mineral density after 6 years. Results demonstrated significantly lower incidence...

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Not sure if you want to join OrthoEvidence?

Access this report without an Account.

Success, an email containing a link to access this report has been sent to your inbox.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

For Reprints and Permissions, click here

Please Login or Join to leave comments.